Broughton has announced it has introduced ISO/IEC 17025-accredited analytical methods for the quantitative determination of cannabinoids in oils and tinctures, using high-performance liquid chromatography with tandem mass spectrometry (HPLC-MS/MS).
The methods also apply to selected e-liquids.
As oils and tinctures continue to diversify in concentration and formulation complexity, reliable analytical measurement has become a central component of product characterisation and quality assurance.
Cannabinoid content can vary depending on raw material source, extraction approach and intended product application.
The ability to quantify cannabinoids accurately in these oil-based matrices is therefore an important step for organisations developing, manufacturing or assessing these products.
The accredited method involves dilution of the oil or tincture in solvent, followed by analytical measurement using calibration curves and internal standard correction to support accuracy.
Results can be reported in mg/mL, percentage concentration, or mg per container, with quantitation of Total THC and Total CBD available.
This supports organisations requiring data for formulation work, batch verification or regulatory documentation.
"The ability to quantify cannabinoids in oil-based products using a validated and accredited method provides increased confidence in the data that informs formulation, quality control and regulatory compliance," said Rowan Baxendale, Development Scientist at Broughton.
The method also supports defined analytical ranges depending on the CBD concentration of the product.
For formulations containing ≤ 20% CBD, quantitation is supported from approximately two and a half mg/g to 245 mg/g.
For formulations containing > 20% CBD, the supported range extends from approximately eight mg/g to more than 800 mg/g.
These ranges allow consistent measurement across both lower- and higher-strength oils and tinctures.
"Providing accredited analytical methods for oils and tinctures reflects our ongoing commitment to supporting organisations with reliable data," added Chris Allen, CEO at Broughton.
"As product formats evolve, having validated measurement frameworks in place helps ensure consistency and clarity in how cannabinoids are assessed."